Amgen makes pipeline cuts, but obesity plans remain the focus

While Amgen didn’t reveal much about upcoming readouts for its highly-anticipated weight loss drugs during third-quarter earnings, the company did detail certain changes to other parts of its pipeline. The drugmaker